Equillium, INC. (EQ) — SEC Filings

Overview

Equillium, INC. (EQ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 15, 2026: Equillium, Inc. filed its Annual Report to Security Holders (ARS) on April 15, 2026, for the period ending December 31, 2025. The report details the company's financial and operational status for the fiscal year 2025. Equillium, Inc. is a pharmaceutical preparations company based in La Jolla, Califo

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 5 bearish, 34 neutral. The dominant filing sentiment for Equillium, INC. is neutral.

Filing Type Overview

Equillium, INC. (EQ) has filed 2 EFFECT, 1 ARS, 1 DEFA14A, 1 S-3, 6 10-Q, 1 8-K/A, 21 8-K, 2 DEF 14A, 2 10-K, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (39)

• EFFECT Filing — EFFECT · Apr 17, 2026
• Equillium Files 2025 Annual Report to Security Holders — ARS · Apr 15, 2026 Risk: low
  Equillium, Inc. filed its Annual Report to Security Holders (ARS) on April 15, 2026, for the period ending December 31, 2025. The report details the company's f
• Equillium Inc. Files DEFA14A Proxy Materials — DEFA14A · Apr 15, 2026 Risk: low
  Equillium, Inc. filed a DEFA14A on April 15, 2026, related to additional definitive proxy soliciting materials. The filing includes various documents and graphi
• S-3 Filing — S-3 · Apr 7, 2026
• Equillium's Registration Statement Declared Effective by SEC — EFFECT · Mar 26, 2026
  Equillium, Inc. (CIK: 0001746466) received notice of effectiveness for its filing (File No.: 333-291510) on March 25, 2026, as indicated by the SEC's acceptance
• Equillium's Losses Mount Amidst Zero Revenue, Bolstered by Equity Raise — 10-Q · Nov 13, 2025 Risk: high
  Equillium, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $18.623 million, a substantial rise from the
• Equillium, Inc. Amends Report on Certifying Accountant Change — 8-K/A · Oct 24, 2025 Risk: low
  Equillium, Inc. filed an amendment (8-K/A) on October 24, 2025, to its report originally filed on September 30, 2025. This amendment pertains to changes in the
• Equillium, Inc. Files 8-K on Corporate Changes — 8-K · Oct 6, 2025 Risk: medium
  Equillium, Inc. filed an 8-K on October 6, 2025, reporting changes related to its certifying accountant, departure/election of directors, appointment of officer
• Equillium, Inc. Files 8-K Report — 8-K · Sep 19, 2025 Risk: low
  On September 19, 2025, Equillium, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating upd
• Equillium, Inc. Files 8-K Under 'Other Events' — 8-K · Sep 4, 2025 Risk: low
  Equillium, Inc. filed an 8-K on September 4, 2025, reporting an event that occurred on August 29, 2025. The filing is categorized under 'Other Events' and does
• Equillium's Q2 Revenue Plummets to Zero Amid R&D Pause, Net Loss Widens — 10-Q · Aug 14, 2025 Risk: high
  Equillium, Inc. (EQ) reported a significant net loss of $5.739 million for the three months ended June 30, 2025, a sharp decline from a net income of $0.468 mil
• Equillium, Inc. Files 8-K on Agreements and Equity Sales — 8-K · Aug 11, 2025 Risk: medium
  Equillium, Inc. filed an 8-K on August 11, 2025, reporting on an entry into a material definitive agreement, unregistered sales of equity securities, and Regula
• Equillium, Inc. Files 8-K on Material Agreements and Financials — 8-K · Aug 4, 2025 Risk: medium
  Equillium, Inc. filed an 8-K on August 4, 2025, reporting on an entry into a material definitive agreement, results of operations, and other events. The filing
• Equillium Faces Listing Rule Concerns — 8-K · Jun 13, 2025 Risk: high
  Equillium, Inc. filed an 8-K on June 13, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates
• Equillium, Inc. Files 8-K on Officer/Director Changes & More — 8-K · May 22, 2025 Risk: medium
  Equillium, Inc. filed an 8-K on May 22, 2025, reporting on events from May 21, 2025. The filing covers the departure of directors or certain officers, the elect
• Equillium Files 10-Q for Q1 2025 — 10-Q · May 14, 2025 Risk: medium
  Equillium, Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial data and business activities
• Equillium, Inc. Files 8-K on Financials — 8-K · Apr 24, 2025 Risk: low
  On April 24, 2025, Equillium, Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition, as well as financial
• Equillium Files Definitive Proxy Statement for 2025 Shareholder Meeting — DEF 14A · Apr 10, 2025 Risk: low
  Equillium, Inc. filed its definitive proxy statement on April 10, 2025, for its annual meeting of stockholders scheduled for May 21, 2025. The filing outlines t
• 10-K Filing — 10-K · Mar 27, 2025
• Equillium, Inc. Files 8-K: Other Events — 8-K · Feb 6, 2025 Risk: medium
  Equillium, Inc. filed an 8-K on February 6, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dolla
• Equillium Faces NASDAQ Delisting Concerns — 8-K · Dec 13, 2024 Risk: high
  Equillium, Inc. filed an 8-K on December 13, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is fa
• Equillium, Inc. Reports Board and Officer Changes — 8-K · Dec 12, 2024 Risk: medium
  Equillium, Inc. filed an 8-K on December 12, 2024, reporting changes related to its board of directors and officers, as well as compensatory arrangements. The f
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Equillium, Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 13, 2024 Risk: medium
  Equillium, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business operations.
• Equillium Appoints New Chief Medical Officer — 8-K · Oct 31, 2024 Risk: medium
  On October 30, 2024, Equillium, Inc. announced the appointment of Dr. Tiffany L. Rose as Chief Medical Officer. Dr. Rose brings extensive experience in clinical
• Equillium, Inc. Files 10-Q for Q2 2024 — 10-Q · Aug 8, 2024 Risk: medium
  Equillium, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its operations. Key event
• Equillium Faces NASDAQ Listing Concerns — 8-K · Jul 23, 2024 Risk: high
  Equillium, Inc. filed an 8-K on July 23, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company's common
• Equillium, Inc. Files 8-K on Financial Condition — 8-K · Jul 18, 2024 Risk: low
  Equillium, Inc. filed an 8-K on July 18, 2024, to report on its results of operations and financial condition. The filing provides an update on the company's st
• Equillium, Inc. Files 8-K for Other Events — 8-K · Jun 4, 2024 Risk: low
  Equillium, Inc. filed an 8-K on June 4, 2024, to report other events and financial statements. The company, incorporated in Delaware, is based in La Jolla, Cali
• Equillium, Inc. Files 8-K on Security Holder Vote Matters — 8-K · May 23, 2024 Risk: low
  Equillium, Inc. filed an 8-K on May 23, 2024, reporting on a submission of matters to a vote of security holders. The filing date for the report is May 22, 2024
• Equillium, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  Equillium, Inc. (EQ) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Equillium, Inc. filed a 10-Q report for the quarter ended March 31, 2024. The
• Equillium, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 11, 2024 Risk: medium
  Equillium, Inc. (EQ) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. Equillium, Inc. will hold its 2024 Annual Meeting of Stockholders virtual
• Equillium, Inc. Files 8-K — 8-K · Apr 1, 2024 Risk: low
  Equillium, Inc. filed an 8-K on April 1, 2024, to report other events. The filing does not contain specific details about the nature of these events, dollar amo
• Equillium, Inc. Files 8-K on Financials — 8-K · Mar 25, 2024 Risk: low
  On March 25, 2024, Equillium, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as fi
• Equillium, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 25, 2024 Risk: medium
  Equillium, Inc. (EQ) filed a Annual Report (10-K) with the SEC on March 25, 2024. Equillium, Inc. filed its 2023 Form 10-K on March 25, 2024, reporting for the
• Equillium Appoints New CMO, Adds Director, Renews CEO Contract — 8-K · Mar 8, 2024 Risk: medium
  Equillium, Inc. announced on March 6, 2024, a series of executive and board changes. Dr. Daniel J. O'Connell has been appointed as the new Chief Medical Officer
• Equillium Files 8-K on Financial Condition and Other Events — 8-K · Feb 23, 2024 Risk: low
  Equillium, Inc. filed an 8-K on February 23, 2024, reporting on its financial condition and other events. The filing indicates the company's business address as
• Equillium Files 8-K for 'Other Event' on Feb 21 — 8-K · Feb 22, 2024 Risk: low
  Equillium, Inc. filed an 8-K on February 22, 2024, reporting an 'Other Event' that occurred on February 21, 2024. The filing indicates a current report pursuant
• Takeda Pharma Discloses 1.84M Share Stake in Equillium — SC 13G · Jan 19, 2024
  Takeda Pharmaceutical Company Limited, a Japanese pharmaceutical giant, reported beneficial ownership of 1,842,977 shares of Equillium, Inc. common stock as of

Risk Profile

Risk Assessment: Of EQ's 33 recent filings, 5 were flagged as high-risk, 14 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Equillium, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $0
• Net Income: -$18.623M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $33.120M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Dr. Tiffany L. Rose
• Class III director
• Dr. Daniel J. O'Connell
• Mr. David M. Smith
• Mr. Bruce L. Downey

Industry Context

Equillium operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success is heavily dependent on clinical trial outcomes and regulatory approvals, with many companies relying on external financing to fund operations.

Top Tags

sec-filing (6) · 8-K (5) · pharmaceuticals (4) · 10-Q (4) · corporate-governance (3) · financial-condition (3) · pharmaceutical (2) · regulatory-filing (2) · Biotechnology (2) · Autoimmune Disorders (2)

Executive Compensation

From the most recent DEF 14A filing (Apr 11, 2024):

• Named Executive Officers — Company's Named Executive Officers

Key Numbers

• ARS Document Size: 2634722 — Size of the ARS PDF document
• Complete Submission Text File Size: 3597757 — Size of the complete submission text file
• Net Loss (9 months): $18.623M — Increased from $2.273M in 2024, indicating higher operating losses.
• Revenue (9 months): $0 — Down from $36.703M in 2024, highlighting lack of product sales.
• Cash and Cash Equivalents: $33.120M — Increased from $18.085M at Dec 31, 2024, due to equity financing.
• Equity Financing Gross Proceeds: $30M — Secured in Q3 2025, providing liquidity for operations.
• Accumulated Deficit: $212.4M — As of September 30, 2025, reflecting significant historical losses.
• Common Shares Outstanding: 60,893,283 — As of November 10, 2025, reflecting dilution from equity raises.
• Liquidity Horizon: 12 months — Management believes current cash will fund operations for at least this period.
• Research and Development Expenses (9 months): $11.307M — Decreased from $30.113M in 2024.
• SEC File Number: 001-38692 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 82-1554746 — Company's tax identification number.
• Revenue for Q2 2025: $0 — down from $13.853 million in Q2 2024, indicating a complete halt in revenue generation
• Net loss for Q2 2025: $5.739 million — compared to net income of $0.468 million in Q2 2024, showing a significant deterioration in profitability
• Net loss for six months ended June 30, 2025: $14.393 million — compared to $2.266 million for the same period in 2024, indicating increased losses

Related Companies

EQIL · EQUL · EQM

Frequently Asked Questions